Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches

Author:

Chukkalore Divya1,MacDougall Kira2,Master Viraj34,Bilen Mehmet Asim45,Nazha Bassel45ORCID

Affiliation:

1. Department of Internal Medicine, Staten Island University Hospital , New York, NY , USA

2. Department of Hematology and Medical Oncology, the University of Oklahoma Medical Center , Oklahoma City, OK , USA

3. Department of Urology, Emory University School of Medicine , Atlanta, GA , USA

4. Winship Cancer Institute of Emory University , Atlanta, GA , USA

5. Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA

Abstract

Abstract Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the use of combination chemotherapy with etoposide, doxorubicin, and cisplatin. The review also focuses on emerging data providing hope for the use of immune checkpoint inhibitors and targeted therapies in ACC with a summary of ongoing trials.

Publisher

Oxford University Press (OUP)

Reference73 articles.

1. Adrenocortical carcinoma: clinical and laboratory observations;Wajchenberg;Cancer,2000

2. Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment;Shariq,2021

3. Adrenocortical carcinoma: clinical update;Allolio,2006

4. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors;Pinto,2004

5. Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database;Tella,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3